Sivia Capital Partners LLC Purchases Shares of 494 IDEXX Laboratories, Inc. $IDXX

Key Points

• Sivia Capital Partners LLC acquired 494 shares of IDEXX Laboratories, valued at approximately $265,000, during the second quarter.
• Analysts are optimistic about IDEXX's stock, with target price increases from firms like BTIG Research ($785) and Jefferies ($625), indicating a general consensus rating of Moderate Buy.
• During its last earnings report, IDEXX Laboratories posted earnings per share of $3.63, exceeding estimates, while revenue increased 10.6% year-over-year to $1.11 billion.

Sivia Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 494 shares of the company's stock, valued at approximately $265,000.

A number of other hedge funds have also modified their holdings of IDXX. MorganRosel Wealth Management LLC acquired a new stake in IDEXX Laboratories during the first quarter valued at $26,000. Migdal Insurance & Financial Holdings Ltd. increased its position in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock worth $35,000 after purchasing an additional 30 shares during the last quarter. WPG Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 1st quarter worth about $37,000. Bank of Jackson Hole Trust lifted its holdings in shares of IDEXX Laboratories by 328.6% during the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock valued at $39,000 after buying an additional 69 shares during the last quarter. Finally, Cornerstone Planning Group LLC grew its stake in shares of IDEXX Laboratories by 108.0% in the 1st quarter. Cornerstone Planning Group LLC now owns 104 shares of the company's stock valued at $44,000 after buying an additional 54 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Michael Lane sold 8,411 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total transaction of $5,279,921.14. Following the completion of the transaction, the executive vice president directly owned 7,132 shares in the company, valued at $4,477,041.68. The trade was a 54.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the sale, the director owned 262 shares in the company, valued at approximately $169,600.46. The trade was a 89.30% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded down $12.06 on Monday, reaching $644.10. 386,847 shares of the stock were exchanged, compared to its average volume of 405,479. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The firm has a fifty day moving average price of $616.70 and a two-hundred day moving average price of $523.10. The stock has a market cap of $51.53 billion, a PE ratio of 53.63, a PEG ratio of 4.25 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the previous year, the company posted $2.44 earnings per share. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Piper Sandler reaffirmed a "neutral" rating and set a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a report on Monday, August 4th. BTIG Research lifted their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Morgan Stanley increased their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research report on Friday, August 15th. Finally, Wall Street Zen raised IDEXX Laboratories from a "buy" rating to a "strong-buy" rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.